Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1. [PDF]
PLoS ONE, 2015 Constitutively active BCR-ABL kinase fusions are causative mutations in the pathogenesis of hematopoietic neoplasias including chronic myelogenous leukemia (CML).
Pamela Y Ting +12 more
doaj +1 more source
Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia [PDF]
Vojnosanitetski Pregled, 2021 Introduction. Additional karyotype abnormalities in the Philadelphia-positive (Ph+) clone can emerge during the progression of chronic myeloid leukemia (CML) and are of-ten associated with the resistance to treatment with tyrosine kinase inhibitors (TKI).
Denčić-Fekete Marija +6 more
doaj +1 more source
T-Lymphoblastic Leukemia With t(9;22): Blast Phase of Chronic Myelogenous Leukemia or BCR-ABL- Positive T-Acute Lymphoblastic Leukemia? [PDF]
American Journal of Clinical Pathology, 2012 T-acute lymphoblastic leukemia/lymphoma (T-ALL) as chronic myelogenous leukemia blast phase (CML-BP) is rare. BCR-ABL–positive T-ALL is extremely rare. In patients without previous/concurrent history of CML, it is difficult to differentiate these 2 entities. Herein we report 3 cases of T-ALL with t(9;22) and review the literature.
Jie Xu, Shaoying Li
openaire +1 more source
A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ ABL Positivity during Chronic Phase [PDF]
Annals of Laboratory Medicine, 2013 Dear Editor CML is characterized by the clonal expansion of bone marrow hematopoietic cells and is associated with the Philadelphia chromosome [1]. The accelerated phase of CML, which is also known as the blast crisis phase, occurs in patients as the disease progresses.
Park, Sang Hyuk +5 more
openaire +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]
, 2018 The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core +1 more source
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
Molecular Cancer, 2007 Background Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia.
Groffen John +7 more
doaj +1 more source
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]
, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet +9 more
core +1 more source
Molecules, 2017 In an attempt to develop potent antitumor agents, new 1,3,4-thiadiazole derivatives were synthesized and evaluated for their cytotoxic effects on multiple human cancer cell lines, including the K562 chronic myelogenous leukemia cell line that expresses ...
Mehlika Dilek Altıntop +9 more
doaj +1 more source
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice [PDF]
Leukemia, 2011 Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML.
C I-U, Chen +11 more
openaire +2 more sources